title: Additive effect of erythropoietin and heme on murine hematopoietic recovery after azidothymidine treatment.
abstract: The ability of combination treatment with erythropoietin (Epo) and heme to rescue hematopoietic activity in mice from the suppressive effect of azidothymidine (AZT) was determined. Exposure of mice to AZT for 5 weeks produced marked anemia, thrombocytopenia, neutropenia, and weight loss, whereas mice that received Epo and heme for 3 subsequent weeks showed significant alleviation of AZT cytotoxicity. Treatment with Epo (10 U for 5 times/week) stimulated hematopoietic recovery in the AZT-treated animals and reduced the severe anemia and thrombocytopenia by 3 weeks. Administration of a lower Epo dose (1 U Epo) resulted in only a modest retardation of AZT-induced anemia, although, when combined with heme, there was a great improvement in recovery of erythropoiesis. The combination of heme with Epo (10 U) produced the optimum response, resulting in almost normal recovery of bone marrow cellularity as well as recovery of burst-forming units-erythroid (BFU-E) and splenic hematopoietic progenitor content (colony-forming unit-spleen [CFU-S]) by the end of 3 weeks of post-AZT treatment. Treatment with heme alone markedly enhanced the recovery of BFU-E and CFU-S, as well as body weight post-AZT; however, this recovery was not to the extent seen in combination with Epo (10 U). Long-term bone marrow cultures (LTBMCs) established from mice exposed to AZT for 8 weeks showed a marked reduction in cellularity and this was completely alleviated when mice received heme and Epo (10 U) for 3 weeks after 5 weeks of AZT administration. The additive effect of heme and Epo was seen in BFU-E production, as well as in CFU-S production, in LTBMCs. Thus, heme exerts a significant protective effect on hematopoietic progenitors in vivo and may be of potential clinical use in combination with Epo to promote effective erythropoiesis in the setting of AZT therapy.
authors.affiliation: Department of Medicine, New York Medical College, Valhalla 10595.
authors.forename: J
authors.initials: J
authors.lastname: Harrison
authors.forename: A
authors.initials: A
authors.lastname: Kappas
authors.forename: R D
authors.initials: RD
authors.lastname: Levere
authors.forename: J D
authors.initials: JD
authors.lastname: Lutton
authors.forename: J L
authors.initials: JL
authors.lastname: Chertkov
authors.forename: S
authors.initials: S
authors.lastname: Jiang
authors.forename: N G
authors.initials: NG
authors.lastname: Abraham
mesh_terms: D000740:Anemia / Q000139:chemically induced; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001854:Bone Marrow Cells; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D004357:Drug Synergism; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006418:Heme / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D015431:Weight Loss; D015215:Zidovudine / Q000633:toxicity*
chemical_list: D004921:Erythropoietin; D006418:Heme; D015215:Zidovudine